Geron reported $519.01M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Amgen USD 95.64B 3.14B Jun/2026
Bio Techne USD 2.55B 27.9M Mar/2026
Cassava Sciences USD 108.37M 9.99M Mar/2026
Cytokinetics USD 1.27B 151.06M Mar/2026
Exelixis USD 2.59B 250.83M Mar/2026
Genmab DKK 12.87B 5.85B Dec/2025
Geron USD 519.01M 15.11M Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
Incyte USD 7.87B 533.53M Jun/2026
MacroGenics USD 217.87M 38.97M Mar/2026
Novartis USD 122.03B 3.5B Jun/2026
Novavax USD 1.04B 133.35M Mar/2026